Anticipating T-cell therapy approval, Adaptimmune secures $125M to fund launch
细胞疗法临床2期免疫疗法引进/卖出
Adaptimmune Therapeutics finalised a debt financing with Hercules Capital on Wednesday worth up to $125 million to prepare for the potential launch of afami-cel, its experimental synovial sarcoma treatment. The engineered, autologous T-cell therapy against MAGE-A4 is currently under priority review at the FDA, with a decision expected by August 4.
The first $25-million tranche will be immediately available to the biotech after the five-year loan agreement closes. Adaptimmune can draw a second $25-million portion after the approval of afami-cel approval, and is eligible to receive an additional $75 million across three tranches, dependent on undisclosed conditions.
According to Adaptimmune, the financing will also aid the launch of its second candidate, lete-cel, which is expected in 2026.
The NY-ESO-targeting cell therapy is in the Phase II IGNYTE-ESO trial in patients with synovial sarcoma and myxoid/round cell liposarcoma (MRCLS).
The financing comes a month after Roche’s Genentech unit ended a 2021 deal with Adaptimmune to develop T-cell therapies for cancer. While the biotech had cashed in $185 million from the tie-up, the amount was a far cry from the $3 billion it was eligible to receive.
更多内容，请访问原始网站
文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。
靶点
-热门报告
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。